Literature DB >> 31235976

Contrast-enhanced Computed Tomography-Guided Percutaneous Cryoablation of Renal Cell Carcinoma in a Renal Allograft: First Case in Asia.

Ichiro Tsuboi1, Motoo Araki, Hiroyasu Fujiwara, Toshihiro Iguchi, Takao Hiraki, Naoko Arichi, Kasumi Kawamura, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Tomoko Sako, Atsushi Takamoto, Koichiro Wada, Yasuyuki Kobayashi, Toyohiko Watanabe, Hiroyuki Yanai, Masashi Kitagawa, Katsuyuki Tanabe, Hitoshi Sugiyama, Jun Wada, Hiroaki Shiina, Susumu Kanazawa, Yasutomo Nasu.   

Abstract

Nephron-sparing treatment should be offered whenever possible to avoid dialysis in allograph cases. Cryoablation is a new treatment option for treating small-sized renal cell cancer (RCCs). We report a case of RCC arising in a kidney allograft treated by cryoablation. To our knowledge, this is the first case in Asia of RCC in a renal allograft treated using cryoablation. Contrast-enhanced CT-guided percutaneous renal needle biopsy and cryoablation were used to identify the RCC, which could not be identified by other techniques. The postoperative course was uneventful. Contrast-enhanced CT also showed no recurrence or metastases at the 6-month follow-up.

Entities:  

Keywords:  cryoablation; partial nephrectomy; renal allograft; renal cell carcinoma; renal transplantation

Year:  2019        PMID: 31235976     DOI: 10.18926/AMO/56871

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  2 in total

1.  An intracapsular nephrectomy for the acquired cystic disease-associated renal cell carcinoma in renal transplant allograft: A clinical case report.

Authors:  Yue Song; Jingjing Zheng; Shiying Guo; Lianhui Fan
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 2.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.